Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DSGN 
Design Therapeutics Inc (DSGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DSGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.85% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 321.19M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 3 | Beta 1.58 | 52 Weeks Range 2.60 - 7.77 | Updated Date 08/29/2025 |
52 Weeks Range 2.60 - 7.77 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.2967 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.02% | Return on Equity (TTM) -26.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 106857430 | Price to Sales(TTM) 22642.01 |
Enterprise Value 106857430 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56948100 | Shares Floating 26277574 |
Shares Outstanding 56948100 | Shares Floating 26277574 | ||
Percent Insiders 35.98 | Percent Institutions 61.03 |
Upturn AI SWOT
Design Therapeutics Inc
Company Overview
History and Background
Design Therapeutics Inc. was founded in 2017 and is a biotechnology company focused on developing gene targeted chimera (GeneTACu2122) molecules for the treatment of diseases caused by inherited nucleotide repeat expansions. It went public in 2020.
Core Business Areas
- GeneTACu2122 Platform: Develops GeneTACu2122 molecules that target the underlying cause of genetic diseases by selectively modulating gene expression.
- Discovery and Development: Focuses on identifying and developing novel GeneTACu2122 therapies for diseases with significant unmet medical needs.
Leadership and Structure
S. Louise Markesbery is the President and CEO. The company has a board of directors and operates with a research and development focused organizational structure.
Top Products and Market Share
Key Offerings
- Friedreich's Ataxia (FA) Program: A GeneTACu2122 molecule designed to reduce GAA repeat expansion-containing transcripts in the FXN gene, which is responsible for FA. It is in preclinical development. Competitors include companies developing gene therapies and small molecule approaches for FA.
- Myotonic Dystrophy Type 1 (DM1) Program: A GeneTACu2122 molecule designed to target and degrade transcripts containing expanded CUG repeats in the DMPK gene, the cause of DM1. It is in preclinical development. Competitors include Ionis Pharmaceuticals (IONS) with their antisense oligonucleotide therapy.
Market Dynamics
Industry Overview
The industry is characterized by rapid advancements in genetic therapies and personalized medicine, with increasing investment in novel therapeutic modalities like gene editing and targeted RNA therapeutics.
Positioning
Design Therapeutics aims to be a leader in the development of GeneTACu2122-based therapies, differentiating itself through its approach to selectively modulating gene expression. Their competitive advantage lies in their GeneTAC platform and targeted approach.
Total Addressable Market (TAM)
The TAM for genetic therapies is substantial, estimated in the billions of dollars, encompassing a wide range of diseases. Design Therapeutics is positioned to capture a portion of this market through its targeted therapies for specific genetic disorders.
Upturn SWOT Analysis
Strengths
- Novel GeneTACu2122 platform
- Targeted approach to gene modulation
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on successful clinical trials
- Limited revenue generation
Opportunities
- Expansion to new disease targets
- Partnerships with pharmaceutical companies
- Positive clinical trial data
- Increasing investor interest in gene therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- IONS
- PTCT
- SRPT
- CRSP
Competitive Landscape
Design Therapeutics is a relative newcomer compared to established players like Ionis Pharmaceuticals and Sarepta Therapeutics. The company's competitive advantage lies in its novel GeneTACu2122 platform, but it faces significant challenges in clinical development and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Design Therapeutics has not yet generated revenue, so historical growth is focused on preclinical development progress and fundraising activities.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential partnerships. Analyst estimates vary widely, reflecting the speculative nature of biotechnology investments.
Recent Initiatives: Recent initiatives include advancing lead programs into clinical trials and expanding the GeneTACu2122 platform to new disease targets.
Summary
Design Therapeutics is an early-stage biotech company with a promising GeneTACu2122 platform. The company is focused on addressing genetic diseases, a high-growth area. A lack of revenue and negative income signals a high-risk high-reward investment. Successful clinical trial outcomes for its lead programs are the key to achieving significant value creation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), Analyst reports, Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.designtx.com |
Full time employees 57 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.